Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ESMO 2025 | Berlin, Germany
Oct 17 - 21, 2025
Presentation
TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast CancerESMO 2025 | Berlin, Germany
Oct 17 - 21, 2025
Presentation
Patient-Reported Outcomes (PROs) with Vepdegestrant (VEP) vs Fulvestrant (FUL) in Patients (pts) with Estrogen Receptor (ER) 1 Gene Mutated (ESR1m) ER+/Human Epidermal Growth Factor Receptor 2 (HER2): Advanced Breast Cancer (aBC) in the Phase 3 VERITAC-2 TrialWMS 2025 | Vienna, Austria
Oct 7 - 11, 2025
Poster
Oral ARV-027 Induces PolyQ-AR Degradation and Improves Muscle Strength and Endurance in a Murine Model of SBMAMDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy ParticipantsMDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First Clinical Trials of ARV-102, a PROTAC LRRK2 Degrader: Characterization of Pathway Engagement in Healthy Volunteers and Patients With Parkinson’s DiseaseISSX 2025 | Chicago, IL
Sep 21 - 24, 2025
Poster
Absorption, Metabolism, Excretion, and Pharmacokinetics of [14C] Vepdegestrant in Healthy Adult ParticipantsACCP 2025 | Phoenix, AZ
Sep 14 - 16, 2025
Poster
A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult ParticipantsSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin LymphomaSOHO 2025 | Houston, TX
Sep 3 - 6, 2025